Earnings Call Summary | Adaptimmune Therapeutics(ADAP.US) Q4 2023 Earnings Conference
Earnings Call Summary | Adaptimmune Therapeutics(ADAP.US) Q4 2023 Earnings Conference
The following is a summary of the Adaptimmune Therapeutics Plc (ADAP) Q4 2023 Earnings Call Transcript:
以下是Adaptimmune Therapeutics Plc(ADAP)2023年第四季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
Adaptimmune Therapeutics reported a closing liquidity of approximately $147 million.
The company expects to see income in the forthcoming years from three sources: remaining balance from GSK, R&D tax credits from the UK government, and payments from Genentech.
It is in a robust collaboration with Genentech that is expected to bring in milestone payments in 2024 and 2025.
The company continues to explore market opportunities and business development conversations to enhance their financing.
Adaptimmune Therapeutics報告的收盤流動性約爲1.47億美元。
該公司預計,未來幾年收入將來自三個來源:葛蘭素史克的剩餘餘額、英國政府的研發稅收抵免和基因泰克的付款。
它與基因泰克進行了強有力的合作,預計將在2024年和2025年帶來里程碑式的付款。
該公司繼續探索市場機會和業務發展對話,以加強融資。
Business Progress:
業務進展:
Adaptimmune Therapeutics has undertaken a corporate restructuring and merger with TCR Squared.
It submitted the first-ever BLA for an engineered cell therapy for a solid tumor indication and plans for commercial launch of Afamicel in 2024, expecting its first patient infusions in Q4 2024.
The company announced plans to become a fully integrated commercial-stage entity, creating, developing, and delivering cell therapies.
Long-term plans include the development of a new product, uzatresgene autoleucel, or uzacel, and possibly utilizing the commercial channels developed for Afamicel for Letecel in the future.
The company has provided hints about an investor day planned in April to share more progress details.
Optimism expressed over the PRAME target program, indicating good safety and efficacy.
Future plans include expansions of the PRAME program through experience leveraged from other indications.
Adaptimmune Therapeutics已進行了公司重組並與TCR Squared合併。
它提交了有史以來第一份針對實體瘤適應症的工程細胞療法的BLA,並計劃於2024年商業推出Afamicel,預計將在2024年第四季度首次爲患者輸液。
該公司宣佈計劃成爲一個完全整合的商業階段實體,創建、開發和提供細胞療法。
長期計劃包括開發新產品uzatresgene autoleucel或uzacel,以及將來可能利用爲Afamicel開發的商業渠道用於Letecel。
該公司已暗示計劃於4月舉行投資者日,以分享更多進展細節。
對PRAME目標計劃表示樂觀,表明良好的安全性和有效性。
未來的計劃包括利用其他跡象的經驗擴大PRAME計劃。
More details: Adaptimmune Therapeutics IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。